MONCTON, NEW BRUNSWICK--(Marketwired - Dec. 15, 2015) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer therapeutics, today announced that it has reached its target enrollment and treatment duration in its Phase 1 trial. The Phase 1 is designed to evaluate the safety and tolerability of SOR-C13 in patients with solid tumor cancers who have failed other treatments. The Phase 1 was conducted at two sites in Canada and at the University of Texas MD Anderson Cancer Center under regulatory submissions filed by Soricimed with both the US Food and Drug Administration and Health Canada. The Company has initiated the compilation of the formal Clinical Study Report and expects to have top-line results from the trial early in Q1 of 2016.
SOR-C13 is a first-in-class peptide in development for the treatment of cancer. SOR-C13 binds with high selectivity and affinity to TRPV6, a calcium channel that is over-represented in solid-tumor cancers. By binding to this channel, SOR-C13 starves cancer cells of calcium that is needed for cell growth and division. As demonstrated in animal models the result is an inhibition of tumor growth. Due to the high specificity of SOR-C13 for its target and its unique mechanism of action this drug candidate may result in fewer and less severe side effects compared to standard cancer chemotherapy. SOR-C13 is the first drug candidate targeting TRPV6 to have entered clinical development anywhere in the world.
Read more: http://www.marketwired.com/press-release/soricimed-completes-phase-1-trial-of-sor-c13-in-advanced-solid-tumour-cancers-2081983.htm